I agree with your points and interpretation.

These are exciting data in my view. As you say, we have to keep in mind the trial was relatively short. The influential LRCCPPT study was more than 7 years, and most CVD prevention studies are for about 5 years. And who knows what the outcome would have been with a higher dose?

The FDA's decision cannot be predicted, of course, but the propsects for the drug (and for the entire epigenetics field) have been enhacned by BETonMACE. I would be amazed if BP is not interested.